Oculocerebrorenal syndrome

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Retrieved on: 
Thursday, November 30, 2023
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, Ras, Pancreatic cancer, NYSE, Policy, CANF, CFO, Exercise, Ascites, Artificial intelligence, Psoriasis, Conquer, RAS, Patient, Inflammation, ASCO, Growth, CKD, Machine learning, Intellectual, DSM-IV codes, Conference, University, Trial of the century, Survival, Phase, Cancer, HCC, AI, Quality of life, Society, TASE, NASH, AACR, Pharmaceutical industry, Medical device, Cryptocurrency, Life insurance, Genetics, Medicine, Oculocerebrorenal syndrome

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results for the nine months ended September 30, 2023.

Key Points: 
  • (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results for the nine months ended September 30, 2023.
  • Financial income, net for the nine months ended September 30, 2023 was $0.38 million compared to financial expense, net of $0.14 million for the same period in 2022.
  • The decrease in financial expense, net was mainly due to revaluation of our short-term investment and increase in interest income from deposits in 2023.
  • The Company's consolidated financial results for the nine months ended September 30, 2023 are presented in accordance with US GAAP Reporting Standards.

Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track

Retrieved on: 
Wednesday, November 1, 2023
Biotechnology, Pharmaceutical, Finance, Oncology, General Health, Health, Professional Services, Clinical Trials, Oculocerebrorenal syndrome, Psoriasis, NYSE, Food, Inflammation, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Artificial intelligence, Liver cancer, CANF, NASH, Partnership, Machine learning, Pancreatic cancer, Consultant, TASE, A3, SLD, Pharmaceutical industry

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today confirmed that all of the Company’s clinical and business development activities are ongoing and proceeding by both its Israeli and US based staff.

Key Points: 
  • (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today confirmed that all of the Company’s clinical and business development activities are ongoing and proceeding by both its Israeli and US based staff.
  • “Can-Fite remains focused and stronger than ever in our purpose to bring medications to market that improve and save lives.
  • All the investigators participating in the conductance of the clinical studies are working full force and continue patient enrolment for the ongoing advanced clinical studies,” stated Dr. Pnina Fishman, Can-Fite’s Chief Scientific Officer and Executive Chairman.
  • Phase II trials include an ongoing study for steatotic liver disease (SLD), formerly known as NASH, and preparatory work is underway for a Phase IIa trial in pancreatic cancer.

Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies

Retrieved on: 
Monday, October 9, 2023
Oncology, Health, Diabetes, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, NYSE, Oculocerebrorenal syndrome, Business, Dermatology, CANF, EMA, FDA, Hepatology, TASE, Business development, Conference, Patient, Pharmaceutical industry

Can-Fite signed recently an agreement with Fondazione Telethon for the co-development of Piclidenoson for the treatment of Lowe syndrome based on breakthrough findings of Dr. Antonella De Matteis that the Can-Fite drug Piclidenoson is efficacious in pre-clincial studies in treating Lowe Syndrome.

Key Points: 
  • Can-Fite signed recently an agreement with Fondazione Telethon for the co-development of Piclidenoson for the treatment of Lowe syndrome based on breakthrough findings of Dr. Antonella De Matteis that the Can-Fite drug Piclidenoson is efficacious in pre-clincial studies in treating Lowe Syndrome.
  • FDA & EMA approvals for rare genetic diseases are faster and require clinical studies with smaller number of patients.
  • Additional meetings with Japanese companies who are interested in the Oncology and Dermatology Can-Fite’s indications will take place as well.
  • “The Lowe Syndrome is Can-Fite’s first rare genetic disease indication and I am happy that it raises high interest of Japanese companies who are experts in the orphan drug arena.

Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Oculocerebrorenal syndrome, Cancer, Conference, NYSE, CANF, Hepatology, DSM-IV codes, TASE, Pharmaceutical industry

(NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced that the Company’s CEO Motti Farbstein will present at the H.C. Wainwright 25th Annual Conference.

Key Points: 
  • (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced that the Company’s CEO Motti Farbstein will present at the H.C. Wainwright 25th Annual Conference.
  • In addition to the presentation, he will conduct one-on-one meetings with investors at the conference.
  • Motti Farbstein will highlight Can-Fite’s advanced stage pipeline including the pancreatic carcinoma and the rare genetic disease Lowe Syndrome latest developments on September 11th.
  • An updated company presentation has been uploaded to the company website.

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Retrieved on: 
Thursday, August 31, 2023
FDA, Health, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Oculocerebrorenal syndrome, University, Journal of Clinical Oncology, Hepatology, University of Naples Federico II, Liver cancer, DSM-IV codes, European Medicines Agency, IDMC, American Society of Clinical Oncology, Survival, Policy, History, WNT, Cancer, Psoriasis, ASCO, EMA, Journal, Patient, Pancreas, CANF, Treatment, TASE, Adolescence, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CKD, SLD, NYSE, HCC, Safety, Food, A3, Society, Medical imaging, Pharmaceutical industry, Cryptocurrency, Life insurance, Medicine, Genetics

In pre-clinical studies, Namodenoson demonstrated a robust anti-growth effect against pancreatic carcinoma, reaching 90% growth inhibition.

Key Points: 
  • In pre-clinical studies, Namodenoson demonstrated a robust anti-growth effect against pancreatic carcinoma, reaching 90% growth inhibition.
  • The FDA requested two Phase III studies and also encouraged the Company to enroll adolescent patients due to Piclidenoson’s strong safety profile demonstrated over its development history and prior clinical studies.
  • The decrease in cash during the six months ended June 30, 2023 is due to the ongoing operations of the Company.
  • The Company's consolidated financial results for the six months ended June 30, 2023 are presented in accordance with US GAAP Reporting Standards.

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Oculocerebrorenal syndrome, University, Prevalence, Hepatology, Marketing, University of Naples Federico II, DSM-IV codes, European Medicines Agency, Lens, Cancer, Syndrome, Biomedical Research, Multimedia, Cataract, Trial of the century, EMA, Molecular medicine, Incidence, Orphan drug, OCRL, Cell biology, Animal, Fondazione Child, CANF, Intellectual, TASE, Diagnosis, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, NYSE, Food, Disease, Pharmaceutical industry, Phosphorus, Medicine, Genetics, Biology

Can-Fite and Fondazione Telethon have signed an agreement outlining their collaboration for the development of Piclidenoson for the treatment of Lowe Syndrome, a high medical need with no drug available.

Key Points: 
  • Can-Fite and Fondazione Telethon have signed an agreement outlining their collaboration for the development of Piclidenoson for the treatment of Lowe Syndrome, a high medical need with no drug available.
  • Fondazione Telethon is an Italian nonprofit organization whose mission is to advance biomedical research toward the diagnosis, cure, and prevention of genetic diseases, and it established TIGEM in 1994.
  • The Company is not aware of any drug candidates currently in development for the systemic treatment of Lowe Syndrome.
  • Piclidenoson for the treatment of Lowe Syndrome may also qualify for the FDA’s Rare Pediatric Disease Priority Review Voucher, granting an accelerated review process for marketing approval.